



THE UNIVERSITY *of* EDINBURGH

Edinburgh Research Explorer

Process evaluation within pragmatic randomised controlled trials

Citation for published version:

French, C, Pinnock, H, Forbes, G, Skene, I & Taylor, SJ 2020, 'Process evaluation within pragmatic randomised controlled trials: what is it, why is it done, and can we find it? – a systematic', *Trials*, vol. 21, no. 1, pp. 916. <https://doi.org/10.1186/s13063-020-04762-9>

Digital Object Identifier (DOI):

[10.1186/s13063-020-04762-9](https://doi.org/10.1186/s13063-020-04762-9)

Link:

[Link to publication record in Edinburgh Research Explorer](#)

Document Version:

Peer reviewed version

Published In:

Trials

General rights

Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22

Title page

Title

Process evaluation within pragmatic randomised controlled trials: what is it, why is it done, and can we find it? – a systematic review

Authors

Caroline French (corresponding author), Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 58 Turner Street, London, E1 2AB. c.french@qmul.ac.uk

Hilary Pinnock, Usher Institute, The University of Edinburgh, Doorway 3, Medical School, Teviot Place, Edinburgh EH8 9AG. hilary.pinnock@ed.ac.uk

Gordon Forbes, Institute of Psychiatry, Psychology and Neuroscience (IoPPN), 16 De Crespigny Park, London, SE5 8AF. gordon.forbes@kcl.ac.uk

Imogen Skene, Emergency Department, Royal London Hospital, Whitechapel, London, E1 1FR. i.skene@nhs.net

Stephanie JC Taylor, Institute of Population Health Sciences, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, 58 Turner Street, London, E1 2AB. s.j.c.taylor@qmul.ac.uk

23 **Abstract**

24 **Background**

25 Process evaluations are increasingly conducted within pragmatic randomised controlled trials (RCTs)
26 of health services interventions and provide vital information to enhance understanding of RCT
27 findings. However, issues pertaining to process evaluation in this specific context have been little
28 discussed. We aimed to describe the frequency, characteristics, labelling, value, practical conduct
29 issues, and accessibility of published process evaluations within pragmatic RCTs in health services
30 research.

31 **Methods**

32 We used a 2-phase systematic search process to 1) identify an index sample of journal articles
33 reporting primary outcome results of pragmatic RCTs published in 2015, then 2) identify all
34 associated publications. We used an operational definition of process evaluation based on the
35 Medical Research Council's process evaluation framework to identify both process evaluations
36 reported separately, and process data reported in the trial results papers. We extracted and
37 analysed quantitative and qualitative data to answer review objectives.

38 **Results**

39 From an index sample of 31 pragmatic RCTs we identified 17 separate process evaluation studies.
40 These had varied characteristics and only three were labelled 'process evaluation'. Each of the 31
41 trial results papers also reported process data, with a median of five different process evaluation
42 components per trial. Reported barriers and facilitators related to real-world collection of process
43 data, recruitment of participants to process evaluations, and health services research regulations.
44 We synthesised a wide range of reported benefits of process evaluations to interventions, trials, and
45 wider knowledge. Visibility was often poor, with 13/17 process evaluations not mentioned in the
46 trial results paper, and 12/16 process evaluation journal articles not appearing in the trial registry.

47 **Conclusions**

48 In our sample of reviewed pragmatic RCTs the meaning of the label 'process evaluation' appears
49 uncertain, and the scope and significance of the term warrant further research and clarification.
50 Although there were many ways in which the process evaluations added value, they often had poor
51 visibility. Our findings suggest approaches that could enhance the planning and utility of process
52 evaluations in the context of pragmatic RCTs.

53 **Registration**

54 Not applicable for PROSPERO registration

55 **Keywords**

56 Process evaluation, pragmatic randomised controlled trials, health services research

57

58 **Background**

59 There are increasing calls for process evaluations alongside outcome evaluations of complex
60 healthcare interventions (1-3). Defining features of 'complex interventions' include having multiple
61 interacting components, addressing multiple outcomes, and targeting different levels of change
62 within complex systems (4). Process evaluations increase understanding of complex healthcare
63 interventions by studying aspects of implementation, mechanisms of impact, and context (4). They
64 may thus shed light on the 'black box' of complex interventions and provide information to interpret
65 outcome results and aid implementation into practice (4, 5). There has been similar increasing
66 interest in the use of pragmatic randomised controlled trials (RCTs) to evaluate the outcomes of
67 complex healthcare interventions (1, 6) . Pragmatic RCTs, in contrast to explanatory RCTs, aim to
68 conduct 'real-world' evaluation of interventions, with findings that have enhanced generalisability to
69 real world clinical practice (6).

70 Masterson-Algar et al. (7) highlight the importance of tailoring process evaluation guidance to the
71 context in which it will be used, and accordingly this review aims to address gaps in knowledge
72 about process evaluation conduct in the context of pragmatic RCTs of health services interventions.
73 The UK Medical Research Council (MRC) published comprehensive guidance for designing and
74 conducting process evaluations of complex interventions in 2014 (4), following earlier process
75 evaluation frameworks by other authors (5, 8, 9). However, apart from Grant et al.'s framework (5),
76 these were developed primarily for public health research. Although being described as applicable
77 to health services research, many of the examples in the MRC's guidance (4) are from a public health
78 perspective. It is therefore useful to review process evaluation conduct in health services settings as
79 these are likely to present some unique challenges. The few published systematic reviews of process
80 evaluation methodology focus on specific fields of clinical practice (10-15) rather than outcome
81 evaluation methods. The pragmatic RCT method is not explicitly addressed in existing process
82 evaluation guidance, although some pertinent methodological issues are discussed, for example
83 avoiding Hawthorne effects from patients participating in process evaluation interviews (4).
84 Nonetheless, concerns have been raised relating to pragmatic RCTs, such as the potential variability
85 of usual care within control groups, and the potential impact of interventions beyond intervention
86 recipients, such as to carers and family members (16). Process evaluations present opportunities to
87 examine and address such issues.

88 This review aims to provide insight into the state of process evaluation in the context of pragmatic
89 RCTs in health services research, along with the reported value, barriers, and facilitators to
90 conducting them. We also examine two issues identified as problematic, both from our own
91 experience and within the process evaluation literature. Firstly, we investigate labelling, as the label
92 'process evaluation' has been applied to many types of study (4), and previous reviews noted
93 inconsistent use of the term (5, 10). We have also anecdotally encountered confusion and multiple
94 interpretations of the meaning of the label. Secondly we examine accessibility as suboptimal

95 reporting has been highlighted, such as time delay and poor linkages between trial and process
96 evaluation results publications (4).

97 Our aims were, within a systematically identified sample of published pragmatic health services
98 research RCTs, to:

- 99 1. Describe the process data reported in trial results papers
- 100 2. Describe the frequency of separate process evaluation publications
- 101 3. Describe use of the label 'process evaluation'
- 102 4. Describe the characteristics of process evaluations
- 103 5. Synthesise reported practical barriers and facilitators to process evaluation conduct
- 104 6. Synthesise the reported values of the process evaluations
- 105 7. Describe the accessibility of process evaluation results

106

107 **Methods**

108 Similar to previous systematic reviews of process evaluations (11, 12) we used a 2-phase search
109 process. We firstly systematically identified an index sample of journal articles reporting the primary
110 outcome results of pragmatic RCTs evaluating health services interventions (hereafter referred to as
111 'trial results papers'), then systematically searched for all associated publications. Using an
112 operational definition of process evaluation based on the MRC's framework (4) we then identified
113 the process evaluations reported in associated publications, regardless of how they were labelled.
114 We also identified any process data reported in index trial results papers which mapped to MRC
115 process evaluation components. Figure 1 illustrates the methods and table 1 shows the MRC
116 process evaluation components.

117 **Figure 1: Methods overview**

Table 1: MRC process evaluation components (adapted from (4), with definitions in italics where provided in original)

CONTEXT		
Causal mechanisms present within the context that act to maintain the status quo, or enhance effects	Contextual factors that shape theory of how the intervention works	Contextual moderators <i>Shape, and may be shaped by, implementation, intervention mechanisms, and outcomes</i>
IMPLEMENTATION		
Dose <i>How much intervention is delivered</i>	Fidelity <i>The consistency of what is implemented with the planned intervention</i>	Adaptations <i>Alterations made to an intervention in order to achieve better contextual fit</i>
How delivery is achieved <i>The structures, resources and mechanisms through which delivery is achieved</i>	Reach <i>Extent to which target audience comes into contact with intervention</i>	
MECHANISMS OF IMPACT		
Mediators <i>Intermediate processes which explain subsequent changes in outcome</i>	Participant responses <i>How participants interact with a complex intervention</i>	Unanticipated pathways and consequences

Search strategy, inclusion and exclusion criteria

In the first search phase we systematically identified an index sample of pragmatic RCTs. We limited the search to a single year, 2015, (selected to allow time for related publications to appear) and to Medline Core Clinical Journals to provide a feasible number of papers. We searched Medline (Ovid), the full search strategy is given in additional file 1.

Phase 1 inclusion criteria (PICOS)

- Population: any
- Intervention: any delivered by a health service
- Comparator: any

- 130 • Outcome: any
- 131 • Study: pragmatic randomised controlled trial (defined as use of the word ‘pragmatic’ to
- 132 describe the RCT in the title or abstract)

133 **Phase 1 exclusion criteria**

- 134 1. Papers not reporting the primary trial outcome
- 135 2. RCTs labelled as pilot, feasibility, or implementation studies.
- 136 3. Trials of health interventions not delivered within health services, for example by charities

137 In phase 1, two reviewers (CF and IS) independently screened titles and abstracts against the

138 inclusion and exclusion criteria, obtaining full-texts as necessary. Any disagreements were discussed

139 with ST and HP to reach a final decision on inclusion.

140 In phase 2 (see figure 1) citation searches for each trial results paper were conducted using both

141 Web of Science (Clarivate Analytics) and Google Scholar. Corresponding authors were sent one

142 reminder if we received no reply following the first contact. The searches were originally conducted,

143 and authors contacted, in March and April 2018. Search phase 2 was updated in December 2019

144 apart from author contact.

145 We used an operational definition of ‘process evaluation’ to identify papers for inclusion regardless

146 of how they were labelled by the study authors. As shown in figure 1, included studies investigated

147 one or more MRC process evaluation components and (to distinguish them from trial secondary

148 analyses or sub-studies) were aimed at increasing understanding of the intervention or trial. One

149 reviewer (CF) screened all publications and discussed all considered to possibly be process

150 evaluations with HP and ST in a consensus meeting to agree the final sample of process evaluations.

151 Several index trials were funded by the UK National Institute for Health Research’s *Health*

152 *Technology Assessment* (HTA) programme. This programme requires results to be published as a

153 monograph in the *Health Technology Assessment* journal, additional to any other journal

154 publications. We therefore reviewed the full texts of all HTA monographs to check for process
155 evaluation results.

156 **Data extraction and analysis**

157 As this was a review of methodology rather than findings, we did not conduct any appraisal of
158 quality of the included process evaluation studies. We extracted quantitative data to an Excel
159 database and conducted descriptive analysis using SPSS v25. We extracted qualitative data as
160 sections of text from PDFs of publications and used NVivo v11 for data management and to aid
161 thematic analysis.

162 Where the methods or results from a single trial or process evaluation were reported in more than
163 one publication (e.g. HTA monograph and separate journal paper) we extracted all available data
164 from all publications but treated the publications as a single case. CF extracted and analysed all data
165 independently, apart from the MRC process evaluation components as detailed below.

166 **Data extracted from the trial results papers**

167 We extracted descriptors of all trials, and the data fields and their operationalisation are shown in
168 additional file 2. We mapped data items reported in the results sections to the MRC process
169 evaluation framework (4) (see table 1) to identify process data within the trial results papers. For
170 example, a trial flow diagram (process data item) mapped to the process evaluation component
171 'reach'. For each trial we recorded whether each process evaluation component was reported in the
172 trial results paper at least once. We piloted this process, and as the MRC guidance does not provide
173 clear definitions for some components, we made a list of the types of data which mapped to each
174 component (for example subgroup analyses mapped to 'contextual moderators'). Three reviewers
175 (CF, GF, and IS) independently extracted data from the first three trials, compared results, and
176 agreed initial mappings. We used these to extract data from four further trials, and again compared

177 and discuss findings. CF then extracted data for the remaining trials, discussing any new mappings
 178 or uncertainties with the other authors.

179 **Data extracted from process evaluation publications**

180 Table 2 shows the outcomes extracted for each process evaluation publication. O’Cathain et al. (17)
 181 noted that the value of qualitative research within RCTs is often not clearly articulated in
 182 publications, and we noted the same during scoping this review. We therefore operationalised
 183 ‘reported value’ as any reported rationales for undertaking a process evaluation, or any reported
 184 implications of having undertaken it or of its findings. This allowed us to capture any anticipated or
 185 observed benefits of the process evaluation or use of the knowledge it produced.

186 **Table 2: Data outcomes for process evaluation publications**

Review objective	Type of data	Outcomes
Labelling	Quantitative	<ul style="list-style-type: none"> • Use of label ‘process evaluation’ anywhere in the set of papers for the trial • Use of keyword ‘process evaluation’ for indexing
Characteristics	Quantitative	<ul style="list-style-type: none"> • Process evaluation components (mapped from aims and qualitative findings) • Whether processes related to the intervention or trial • Methodology • Data collection method
Reported barriers and facilitators	Qualitative	<ul style="list-style-type: none"> • Practical issues relating to designing or operationalising the process evaluation
Reported value	Qualitative	<ul style="list-style-type: none"> • Reported rationales for undertaking, or implications of the process evaluation
Accessibility	Quantitative	<ul style="list-style-type: none"> • Publishing journal • Time to publication from trial results paper • Search method required to locate paper • Mention of the process evaluation in trial results paper • Where in paper the trial first named or referenced

		• Inclusion in trial registry
--	--	-------------------------------

A completed PRISMA checklist is in additional file 3

Results

Figure 2 shows the results of search phases 1 and 2. The first search phase yielded 31 journal articles reporting primary outcome results from pragmatic RCTs, and the second phase located 133 associated publications. We categorised 21 of these 133 associated publications as process evaluation results. These covered 17 separate process evaluation studies, as some were published in more than one paper.

Figure 2: Adapted PRISMA flow diagram (18)

[footnote for figure 2] *searches conducted in order stated and each record included only under search method first found

Characteristics of the sample of pragmatic RCTs

The sample of pragmatic RCTs (n=31) was highly variable in terms of intervention and trial characteristics (see additional file 4 for details of the RCTs). They covered 20 different clinical specialties and 17 different combinations of professionals involved in intervention delivery. Most interventions (28/31) were received by patients only, with the remainder directed at staff or staff and patients. Table 3 summarises further characteristics of the included trials.

Table 3: Characteristics of the index sample of pragmatic RCTs

Randomisation level		Comparator	
Individual	25	Usual care	15
Cluster	6	Other intervention(s)	10
Design		Stepped-wedge control period	2
2-arm	22	Comparing two settings	1
Non-inferiority (2-arm)	4	Comparing two deliverers	1
3-arm	3	No intervention	1
Crossover	1	Sham clinical procedure	1
Stepped-wedge	1	Publishing journal	
Primary outcome result		British Medical Journal	7
No evidence of effect	15	Lancet	7
Evidence of effect	11	JAMA	5
Non-inferiority trial	4	Canadian Medical Association Journal	2
Unclear	1	JAMA Pediatrics	2
Funder		Critical Care Medicine	1
Public	25	Gut	1
Multiple funders	3	JAMA Internal Medicine	1
Charity	1	JAMA Psychiatry	1
Independent Organisation	1	Journal of Allergy and Clinical Immunology	1
Not reported	1	New England Journal of Medicine	1
Type of intervention		Nursing Research	1
Pharmacological treatment strategy	9	The American Journal of Psychiatry	1
Clinical procedure	4	Country	
Therapy intervention	4	UK	12
Clinical treatment strategy	3	USA	8
Model of care provision	3	Australia	3
Reminder system	3	Netherlands	2
Health promotion	3	Brazil	1
Medical device	2	Canada	1
		France	1
		France, Belgium and Switzerland	1
		Hong Kong	1
		North America*	1

*Countries not specified in original article

Process evaluations

Twelve of the 31 pragmatic RCTs had at least one associated publication which we classified as reporting process evaluation results. We identified 17 distinct process evaluation studies, with two trials (19, 20) having three process evaluations and one trial (21) having two process evaluations. Although it is likely that these multiple process evaluation studies in the same trials formed part of one overall process evaluation, as each was presented as a distinct study, we extracted data from each individually. The 17 process evaluation studies were published across 21 publications, as some were published in both a journal article and HTA monograph.

The 17 process evaluation studies are listed in table 4.

Table 4: Included process evaluation studies [multi-page table, please find at end of this document]

Labelling

In the trial results papers the label ‘process evaluation’ was never used to describe the process data. Five trials (19, 43-46) used variations of the labels ‘process outcome’ or ‘process measure’ for some data, although this use was infrequent and inconsistent.

Only three of the 17 studies we classified as process evaluations were labelled as process evaluations (30, 31, 33, 34). One further study was not explicitly labelled as a process evaluation but this was implied as the MRC process evaluation guidance was cited as a rationale for undertaking it (28). Only one of the three studies labelled as ‘process evaluation’ was clearly labelled as such in the article title (31). One was described as ‘informing a process evaluation’ in the main article text (30). The other was referred to as a process evaluation by the trial results paper (47), but not labelled as such in the journal article (33) or HTA monograph (34) reporting it.

Notably, one trial (19) had three qualitative studies published in the same journal: a qualitative interview study labelled as ‘a process evaluation’ (31), a qualitative questionnaire study reported as ‘informing the process evaluation’ (30), and a qualitative interview study labelled as a ‘qualitative evaluation’ (29). However the articles indicated that the studies were interlinked, and formed a ‘sequential mixed-methods study’ (31).

None of the journal articles reporting process evaluation results (n=16) used the keyword “process evaluation”.

Characteristics of process evaluation studies

Of the 17 process evaluation studies identified nine were quantitative (22, 24-28, 32, 37, 39, 40) and eight qualitative (23, 29-31, 34-36, 38, 41, 42). The three labelled as process evaluations were all qualitative (30, 31, 33, 34). There were a variety of data collection methods as can be seen in table

4, with the use of trial data (n=5), interviews (n=4), and questionnaires (n=3) being most common.

The reporting articles of three quantitative process evaluations (25, 27, 37) also presented detailed descriptions of trial or process evaluation methods.

Twelve process evaluations evaluated only intervention processes (22, 24, 28-31, 33-36, 38-42), and five evaluated both trial and intervention processes (23, 25-27, 32, 37). Of the latter, one explored patients' experiences of trial participation qualitatively (23) and two described in detail the trial processes undertaken to ensure fidelity (27, 37). One investigated the trial processes for defining the pragmatic RCT trial population, by undertaking independent assessment of the radiographs used by recruiting surgeons to determine trial inclusion (25). Another investigated the impact of surgeon and patient treatment preferences on trial recruitment and adherence to trial follow up (32).

Further details of the processes evaluated by all 17 studies can be found in table 4.

Process evaluation components reported in the trial results papers and process evaluation papers

All 31 pragmatic RCTs reported process data in their trial results paper(s), with a median of five different MRC process evaluation components (IQR=3; range 1-9) reported at least once per trial results paper. Further details can be found in additional file 4.

Figure 3 shows the percentages of pragmatic RCTs (n=31) reporting each MRC process evaluation component in their trial results paper(s), and the percentages of process evaluation studies (n=17) reporting each component.

Figure 3: MRC process evaluation components reported in the trial results papers and process evaluations

Although we found most of the identified process evaluation components to be reported in the main trial papers and/or in papers labelled process evaluations, the component 'how delivery is achieved' was only reported in process evaluation papers and 'dose' was only reported in trial results papers.

The other ‘implementation’ components – ‘fidelity’, ‘adaptations’, and ‘reach’ were more frequently reported in the trial results papers than the process evaluation papers.

Additional file 4 lists the included 31 pragmatic RCT results papers, and the process evaluation components reported in each. Additional file 5 shows the data items we mapped to each process evaluation component in the trial results papers and process evaluation papers.

Barriers and facilitators to conducting process evaluations

We identified three main themes of reported barriers and facilitators to conducting process evaluation within pragmatic RCTs, shown in figure 4. These themes were: collecting complete and accurate data in health services settings; recruiting the process evaluation participants; and complex regulatory systems (only barriers identified within this theme).

Figure 4: Reported barriers and facilitators

Reported value of the process evaluation studies

We identified three main themes relating to the reported value of the process evaluation: 1) whether the process evaluation added value to the intervention; 2) whether the process added value to the trial; or 3) whether the process evaluation’s value related to something external to the trial and intervention. Figure 5 shows main themes and sub-themes, and table 5 shows the number of process evaluations mentioning each subtheme and examples of data relating to each subtheme. A full table of all data for each subtheme is in additional file 6.

Figure 5: Synthesis of reported values of process evaluation studies

Table 5: Reported value subthemes

Subtheme	Number of process evaluations reporting this value (n=17)	Examples of reported values in subtheme

Adding to wider knowledge	16	Informing future trial design (23, 25, 27, 28, 32, 33, 38) Improving future design of similar interventions (22, 24, 33)
Informing post-trial transfer of intervention to practice	15	Providing evidence of feasibility (28, 33) Highlighting potential disadvantages of intervention to facilitate consent discussions with patients (23)
Identifying intervention improvements	10	Adding stronger monitoring protocols to promote adherence (33) Recommendation to research effectiveness over time (29)
Providing reasons for trial results	8	Reasons for non-positive results (33, 38) Reasons for positive results (28-31, 35)
Addressing an identified concern about the intervention	7	Concern about effect of cognitive impairment on effectiveness (22) Concern about participant adherence (33, 35)
Adding information not provided by the trial	6	Participant and deliverer experiences and perceptions (23, 35) Nuance and context (23)
Increasing accuracy of trial results	6	Investigating threats to internal validity (26) Accurately defining trial population (25)
Understanding how the intervention works	4	Understanding what was delivered in a flexible intervention (38) Mechanisms of impact (28)
Building on trial data	2	Exploring findings of subgroup analysis (29)
Understanding applicability of trial results	2	Evaluating whether intended pragmatic trial population achieved (25)
Improving usual care at trial sites	1	Highlighting gaps in current care provision (27)
Meeting pragmatic RCT reporting requirements	1	Adhere to reporting standards for pragmatic and non-pharmacological trials (27)
Meeting recommendation to conduct process evaluation	1	Following MRC recommendations (28)

284

285 **Reported value specifically relating to the pragmatic RCT**

286 The reports of three process evaluations belonging to the same trial (25-27, 32) (not labelled as
287 process evaluations) discussed the pragmatic nature of the trial and the process evaluations'
288 contributions in detail. All highlighted how they supported validity of trial results, by addressing
289 potentially problematic areas of the pragmatic trial design. In one process evaluation (25, 26)
290 authors report it confirmed that the achieved trial sample was pragmatic as intended, and endorsed
291 the pragmatic methods used to determine trial eligibility. In another (26, 27) authors describe how
292 it provided evidence of a good standard of, and therefore comparable, real-world clinical practice in
293 the intervention and usual care delivered in the pragmatic trial across trial sites. In the final process

294 evaluation (26, 32) the impact of patient and surgeon preference on internal and external validity is
295 investigated, acknowledging that this is a threat to the validity of trial findings from the real-world
296 setting.

297 No other reports explicitly discussed the pragmatic nature of the RCT. However one process
298 evaluation (38) used a qualitative content analysis to 'describe the pragmatic reality' of intervention
299 delivery, and its authors emphasise that this was important to allow post-trial replication of a
300 flexible intervention with a large potential variability of delivery in a complex setting. In the report
301 of a qualitative interview study with intervention recipients and providers (42), authors highlight
302 that these process evaluation data provide real-life insights to aid post-trial implementation.

303 **Accessibility of process evaluation studies**

304 Thirteen of the 17 process evaluation studies (22, 24, 28-32, 35-38, 40-42) had no mention in their
305 corresponding index trial results papers.

306 Journal articles reporting process evaluation results (n=16) were published a median of 15.5 months
307 (range -3 – 42; IQR 18.25) after the corresponding index trial results papers. None were published in
308 the same journals as the trial results papers. Two trials had multiple process evaluation studies
309 published in the same journals (25, 27, 29-31). Twelve of the 16 process evaluation journal articles
310 (22, 28-32, 35, 37-39, 41) were not included in the trial registry entries. A forward citation search of
311 the index trial results paper was required to locate 9/16 of the process evaluation journal articles.

312 Two process evaluation journal articles (37, 38) did not appear in the trial results paper, trial registry,
313 or forwards citation searches. These were located by chance before contacting authors as they were
314 mentioned in other papers associated with the trials. All process evaluation journal articles named
315 or referenced the corresponding trial, however 9/16 did not name or explicitly link it to the trial in
316 the title or abstract (22, 24, 25, 29-31, 39-41).

Six of the 12 trials with process evaluation(s) were funded by the UK NIHR HTA programme and published an HTA monograph (23, 26, 34, 36, 42, 48). One process evaluation was only reported in the HTA monograph (23), not a journal article. Six process evaluation studies were published at least in part in both a journal article (25, 27, 32, 33, 35, 41) and HTA monograph (26, 34, 36, 42). Two process evaluations were part of HTA funded trials, however results were not reported in the HTA monographs, only in journal articles (28, 38).

The five HTA monographs reporting process evaluation findings (23, 26, 34, 36, 42) all appeared in the trial registry and were published a median of 1 month (IQR 3; range 0-4) after the trial results papers. Combining publication data for journal articles and HTA monographs therefore improved these aspects of accessibility for the whole sample of process evaluations (n=17). If the earliest of the HTA monograph and journal article for each process evaluation is included, process evaluation studies (n=17) were published a median of five months (range 0-36; IQR 15.5) after the trial results. Similarly, 9/17 process evaluations were published in a publication included in the trial registry entry.

Discussion

Summary of findings

We identified a range of reported benefits of process evaluations to the interventions they evaluated, to the associated pragmatic RCTs, and beyond to wider knowledge. Nonetheless, only approximately one third (12/31) of the pragmatic RCTs included in this review had published process evaluations. However, many data items were reported in trial results papers, which we mapped to MRC-defined process evaluation components. Very few (3/17) studies which we categorised as process evaluations were labelled as such, and the label was used inconsistently in those which did employ it. The 17 process evaluations utilised a variety of qualitative and quantitative methods and examined a wide range of process evaluation components, including trial processes. We identified several practical barriers and facilitators to their design and conduct, and found visibility and

accessibility of process evaluation results were often suboptimal. We now discuss these findings and draw recommendations, with a summary of recommendations presented in table 6.

Value, inclusion, and definitions

In the design and evaluation of complex interventions there is increasing recognition that process evaluations are necessary (2), and calls for their routine inclusion (1). In support of this, we identified a wide range of ways in which process evaluations may add value to interventions and trials. Some of the values we identified resonate with previous reviews (10, 49), such as informing post-trial implementation of interventions into practice and contributing to wider knowledge. We also identified some less recognised, for example improving the standard of care at trial sites by exposing gaps in current care provision (27). These findings are useful to researchers to aid reflection on the potential value of process evaluations, and articulation of this to stakeholders. We did not investigate whether the reported value of the process evaluations related to whether or not the associated trial showed evidence of effect, however this would be useful to include in future reviews.

Our findings suggest that, at least in 2015, process evaluations were far from routine in the health services research context. Nonetheless, our mapping of process evaluation components to outcomes reported in the trial results papers suggests that process was considered, even if they did not publish a separate process evaluation paper. This leads us to question the definition of process evaluation. Our perception of a process evaluation is that it is more substantial than measuring a single process outcome, however when extensive process data are reported within trial results the distinction between ‘a process evaluation’ and this suite of process data is less clear.

Further need for definitional clarity is demonstrated by the paucity and inconsistency of use of the label ‘process evaluation’ in the 17 separate studies. This echoes a finding of a previous systematic review (10), which reported only 32 of 124 ‘process evaluations’ used the label – a similar proportion to the labelling in our studies.

The MRC guidance (4) states that there is no unified definition of process evaluation, and the theoretical scope laid out in process evaluation frameworks and guidance (4, 5, 8, 9) is very broad, encompassing many methods, areas of investigation, and scales of study. This wide variety of possible characteristics of process evaluation is likely to generate confusion and may explain the inconsistent use of the label. Furthermore, the MRC guidance (4) only discusses process evaluation of interventions, however in common with other authors (5, 50-53) we identified the important role for process evaluation in evaluating trial processes, such as recruitment and patient experience of trial participation. We therefore believe simply repeating previous calls for clearer labelling (5) is insufficient and recommend further discussion about the meaning of the term 'process evaluation'.

Barriers and facilitators

We identified several barriers and facilitators to process evaluation researchers collecting optimal data, recruiting participants, and working within regulatory frameworks in the real-world health service contexts in which pragmatic RCTs operate. Several of these identified challenges and enablers are not addressed in the MRC guidance (4), however a previous systematic review (10) recommended monitoring and reporting process evaluation recruitment. We recommend researchers continue to share their experiences of challenges and successful strategies for conducting process evaluations in this context.

Indexing and visibility

Process evaluations often had poor visibility through not being mentioned in trial results papers, and/or not included in trial registries. Furthermore, time delay to publication, not naming trials in titles or abstracts, and not labelling or indexing as process evaluations were significant barriers to locating articles in citation searches. Reporting guidance for process evaluations is available (4, 5), emphasising the importance of linking outcome and process evaluation papers. Our findings demonstrate the importance of following these recommendations, specifically that outcome results journal articles should mention that a process evaluation was undertaken, and process evaluation

journal articles should name or explicitly link to the trial in their title or abstract. We additionally recommend process evaluation articles are included in trial registries, and that mention of any process evaluation undertaken could usefully be added to relevant CONSORT trial reporting checklists (54, 55). We also highlight that some HTA monographs reported process evaluations alongside trial outcomes and integrated discussion of findings (23, 26, 34, 36, 42), and therefore demonstrate a useful reporting format.

Table 6: Summary of recommendations

Recommendations for process evaluation design	<ul style="list-style-type: none"> Consider the identified potential values of process evaluation within pragmatic RCTs and how these may be realised and articulated to stakeholders We encourage debate about the meaning of the label 'process evaluation' and how it may be more consistently applied
Recommendations for process evaluation conduct	<ul style="list-style-type: none"> Consider the identified barriers and facilitators and how to address these when conducting process evaluations in health services settings
Recommendations for process evaluation dissemination	<ul style="list-style-type: none"> Ensure process evaluation publications are included in the trial registry entry Ensure process evaluations are mentioned in journal articles reporting the parent trial, and consider adding this item to relevant CONSORT checklists Ensure process evaluation publications name or refer to the parent trial in the title or abstract Publish strategies for conducting successful process evaluations and addressing challenges in health services settings, such as to recruiting process evaluation participants and collecting data

Strengths and limitations

The key design strength of this review was using an index sample of pragmatic RCTs, then identifying any reported 'process evaluation' using an operational definition. This provided valuable information on process evaluation frequency and accessibility, and highlighted inconsistency of use of the 'process evaluation' label. However, a limitation is that we could include only a sample of pragmatic RCTs. Limiting to trials published in MEDLINE *Core Clinical Journals* means findings are likely reflective of well-funded health services research trials but may not be representative of trials

407 published elsewhere. We also only included RCTs described as ‘pragmatic’ in the title or abstract.
408 As such labelling is not an essential reporting criterion for pragmatic RCTs (54), trials were not
409 identified for inclusion if they only used the term ‘pragmatic’ elsewhere in the paper.

410 Limiting index trial inclusion to publication in 2015 ensured a reasonable length of time for
411 publication of process evaluation papers, and indeed two process evaluations were published in
412 2019. However, this also means findings may not be representative of process evaluations being
413 designed and conducted now. Our findings can therefore only highlight potential areas of
414 uncertainty, difficulty, or opportunity, with alternative research approaches such as surveys or
415 interviews needed to examine current practice. We also acknowledge as a limitation that we used
416 the MRC process evaluation framework to identify and describe process evaluations, when most
417 process evaluations in our sample (associated with trials published in 2015) would very likely have
418 been designed prior to publication of the MRC guidance (4).

419 The search methods for identifying associated publications were comprehensive, with a good
420 response rate from authors. We used a robust process for deciding which publications to categorise
421 as process evaluations, and the team included highly experienced health service researchers with
422 experience of designing and conducting process evaluations. We acknowledge others may disagree
423 with our operational definition and categorisations, however highlight this ambiguity is itself an
424 important finding.

425 Double data extraction was carried out on fields we considered to be subjective, increasing the
426 reliability of findings. There are currently no agreed quality assessment standards for process
427 evaluations (4) and therefore we did not appraise the quality of included studies, however doing so
428 would add to and strengthen the findings.

429

430 **Conclusion**

This review provides valuable insight into the frequency and characteristics of process evaluations, within a sample of systematically identified index pragmatic RCTs published in a single year, and highlights challenges and enablers to their practical conduct in health services settings. Significantly, it suggests that the definition of process evaluation is inconsistent, and that the meaning of the term requires clarification. Despite the wide range of identified values of process evaluations this review highlights important problems with accessibility, which are likely barriers to fully realising this value. Often process evaluations are invisible in pragmatic RCT reporting, and we therefore make several straightforward but significant reporting recommendations.

List of abbreviations

HTA – Health Technology Assessment (UK *National Institute of Health Research* funding programme)

MRC – Medical Research Council

RCT – randomised controlled trial

Additional files

File	File name	Title	Description
Additional file 1	Additional file 1.doc	MEDLINE (Ovid) search strategy	MEDLINE (Ovid) search strategy
Additional file 2	Additional file 2.doc	Trial descriptor data fields	Trial descriptor data fields
Additional file 3	Additional file 3.doc	PRISMA 2009 checklist	Completed PRISMA checklist (NB: page numbers correct in submitted manuscript)
Additional file 4	Additional file 4.doc	Included pragmatic RCTs	Details and references of the 31 index pragmatic RCTs
Additional file 5	Additional file 5.doc	Items mapped to each process evaluation component	Items mapped to each process evaluation component

Additional file 6	Additional file 6.doc	All extracted values of process evaluation	All extracted values of process evaluation
-------------------	-----------------------	--	--

446

447

448 **Declarations**

449 **Ethics approval and consent to participate**

450 Not applicable

451 **Consent for publication**

452 Not applicable

453 **Availability of data and materials**

454 The datasets used and/or analysed during the current study are available from the corresponding
455 author on reasonable request.

456 **Competing interests**

457 The authors declare they have no competing interests

458 **Funding**

459 CF was funded by a PhD studentship awarded by Queen Mary University of London. This report is
460 independent research supported by the National Institute for Health Research. ST is supported by
461 the National Institute for Health Research ARC North Thames. The views expressed in this
462 publication are those of the authors and not necessarily those of the National Institute for Health
463 Research, the NHS or the Department of Health and Social Care.

464 **Authors' contributions**

465 CF, supervised by ST and HP, designed the review and conducted the searches, data extraction, and
466 analysis. GF and IS undertook double data extraction and checking. All authors read and approved
467 the final manuscript.

468 **Acknowledgements**

469 Thank you to all corresponding authors.

470 Thank you to Dr Nina Fudge for reviewing draft manuscripts, and to Paula Funnell, faculty liaison
471 librarian, for advising on the search strategy.

472

Table 4

Reference(s)	Description of process evaluation	Methodology and data collection methods	Intervention or trial processes	Process evaluation components	Labelled as process evaluation
Ball 2018 (22)	Investigated effect of mild cognitive impairment in participants on intervention outcome	Quantitative, Trial dataset	Intervention	Contextual moderators	No
Clark 2015 (23)	Explored patient perceptions of acceptability of intervention in both groups, and motivations for agreeing or refusing to participate in the trial	Qualitative, Interviews	Intervention and trial	Participant responses Reach Contextual moderators Unintended consequences Causal mechanisms in context	No
Grubbs 2015 (24)	Investigated which factors predicted patient uptake of an element of the intervention found to mediate the primary outcome	Quantitative, Medical record review	Intervention	Contextual moderators	No
Handoll 2016 (25) Handoll 2015 (26)	Described how the intended fracture population was practically achieved in pragmatic RCT, including results of formal independent assessment and classification of trial fractures	Quantitative, Detailed author description, Trial dataset	Intervention and trial	Reach	No
Handoll 2014 (27) Handoll 2015 (26)	Described processes undertaken to ensure usual care received by both groups in trial was good quality and comparable, including results of methods described	Quantitative, Detailed author description, Deliverer self-report	Intervention and trial	How delivery is achieved Fidelity	No
Hall 2017 (28)	Investigated mediators of intervention outcome	Quantitative, Trial dataset	Intervention	Mediators	No
Hill 2016 (29)	Explored perceptions of ward staff about how intervention contributed to outcome, and experience of	Qualitative, Focus groups	Intervention	How delivery is achieved Participant responses Contextual moderators	No

Reference(s)	Description of process evaluation	Methodology and data collection methods	Intervention or trial processes	Process evaluation components	Labelled as process evaluation
	intervention being delivered on their ward			Causal mechanisms in context Contextual factors shaping intervention theory	
Hill 2016 (30)	Explored patient experiences of intervention and perceived barriers to engagement	Qualitative, Semi-structured questionnaires	Intervention	Participant responses Causal mechanisms in context Contextual factors shaping intervention theory	Yes
Hill 2015 (31)	Explored perceptions of intervention deliverers of delivering intervention and how the intervention worked	Qualitative, Focus groups, interview, field notes, intervention notes	Intervention	How delivery is achieved Contextual factors shaping intervention theory Participant responses Causal mechanisms in context	Yes
Keding 2019 (32) Handoll 2015 (26)	Explored how patient and surgeon treatment preferences impacted recruitment, trial conduct, and patient outcomes	Quantitative, Trial dataset	Intervention and trial	Reach Participant responses Contextual moderators	No
Knowles 2015 (33) Littlewood 2015 (34)	Explored patient experiences of the intervention, including acceptability, ease of use, barriers to engagement, content, accessibility, and support. Also explored healthcare professional perceptions of feasibility and which patients intervention most suited to.	Qualitative, Interviews	Intervention	Participant responses How delivery is achieved Reach Causal mechanisms in context Contextual moderators Unintended consequences Contextual factors shaping intervention theory	Yes
Nichols 2017 (35) Williams 2015 (36)	Explored experiences of patients about intervention, with focus on patient adherence, and how changed over time	Qualitative, Interviews (longitudinal)	Intervention	Participant responses Causal mechanisms in context Contextual moderators How delivery is achieved	No
Novak 2015 (37)	Investigated whether and how trial sites supplied thawed plasma in a timely manner	Quantitative, Detailed author description,	Intervention and trial	Fidelity How delivery is achieved	No

Reference(s)	Description of process evaluation	Methodology and data collection methods	Intervention or trial processes	Process evaluation components	Labelled as process evaluation
		Observation, reports from sites			
Sands 2016 (38)	Explored how the flexible complex intervention was delivered in real-world complex settings	Qualitative, Trial dataset	Intervention	How delivery is achieved Adaptations Contextual moderators Participant responses Unintended consequences Contextual factors shaping intervention theory Fidelity	No
Saville 2016 (39)	Explored preferences and experiences of intervention deliverers about various aspects of intervention	Quantitative, Questionnaire	Intervention	How delivery is achieved	No
Tjia 2017 (40)	Investigated patients' perceptions of benefits and drawbacks of intervention	Quantitative, Questionnaire	Intervention	Participant responses	No
Vennik 2019 (41) Williamson 2016 (42)	Explored views and experiences of parents and practice nurses of intervention and usual care	Qualitative, Interviews	Intervention	Participant responses How delivery is achieved Contextual factors shaping intervention theory Causal mechanisms in context Unintended consequences	No

References

1. Barratt H, Campbell M, Moore L, Zwarenstein M, Bower P. Randomised controlled trials of complex interventions and large-scale transformation of services. *Health Services and Delivery Research*. 2016;4(16):19–36.
2. Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: Medical Research Council guidance. *British Medical Journal*. 2015;350:h1258.
3. Raine R, Fitzpatrick R, Barratt H, Bevan G, Black N, Boaden R, et al. Challenges, solutions and future directions in the evaluation of service innovations in health care and public health. *Health Services and Delivery Research*. 2016;4(16).
4. Moore G, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of complex interventions: UK Medical Research Council (MRC) guidance. London: MRC Population Health Science Network; 2014.
5. Grant A, Treweek S, Dreischulte T, Foy R. Process evaluations for cluster-randomised trials of complex interventions: a proposed framework for design and reporting. *Trials*. 2013;14(1):15.
6. Loudon K, Treweek S, Sullivan F, Donnan P, Thorpe KE, Zwarenstein M. The PRECIS-2 tool: designing trials that are fit for purpose. *British Medical Journal*. 2015;350:h2147.
7. Masterson-Algar P, Burton CR, Rycroft-Malone J. The generation of consensus guidelines for carrying out process evaluations in rehabilitation research. *BMC Medical Research Methodology*. 2018;18(1):180.
8. Steckler AB, Linnan L. Process evaluation for public health interventions and research. San Francisco Jossey-Bass; 2002.
9. Baranowski T, Stables G. Process evaluations of the 5-a-Day projects. *Health Education and Behavior*. 2000;27(2):157-66.
10. Masterson-Algar P, Burton CR, Rycroft-Malone J. Process evaluations in neurological rehabilitation: a mixed-evidence systematic review and recommendations for future research. *BMJ Open*. 2016;6(11):e013002.
11. Yeary KH, Klos LA, Linnan L. The examination of process evaluation use in church-based health interventions: a systematic review. *Health Promotion Practice*. 2012;13(4):524-34.
12. Wierenga D, Engbers LH, Van Empelen P, Duijts S, Hildebrandt VH, Van Mechelen W. What is actually measured in process evaluations for worksite health promotion programs: a systematic review. *BMC Public Health*. 2013;13(1):1190.
13. Robbins SCC, Ward K, Skinner SR. School-based vaccination: a systematic review of process evaluations. *Vaccine*. 2011;29(52):9588-99.
14. Murta SG, Sanderson K, Oldenburg B. Process evaluation in occupational stress management programs: a systematic review. *American Journal of Health Promotion* 2007;21(4):248.
15. Munodawafa M. Process evaluations of task sharing interventions for perinatal depression in low and middle income countries (LMIC): a systematic review and qualitative meta-synthesis. *BMC Health Services Research*. 2018;18(1).
16. Nicholls SG, Carroll K, Zwarenstein M, Brehaut JC, Weijer C, Hey SP, et al. The ethical challenges raised in the design and conduct of pragmatic trials: an interview study with key stakeholders. *Trials*. 2019;20(1):765.
17. O’Cathain A, Thomas KJ, Drabble SJ, Rudolph A, Goode J, Hewison J. Maximising the value of combining qualitative research and randomised controlled trials in health research: the QUALitative Research in Trials (QUART) study—a mixed methods study. *Health Technology Assessment*. 2014;18(38).
18. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Annals of Internal Medicine*. 2009;151(4):264-9.
19. Hill AM, McPhail SM, Waldron N, Etherton-Beer C, Ingram K, Flicker L, et al. Fall rates in hospital rehabilitation units after individualised patient and staff education programmes: a pragmatic, stepped-wedge, cluster-randomised controlled trial. *Lancet*. 2015;385(9987):2592-9.

20. Rangan A, Handoll H, Brealey S, Jefferson L, Keding A, Martin BC, et al. Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: the PROFHER randomized clinical trial. *JAMA*. 2015;313(10):1037-47.
21. Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M, et al. Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. *Lancet*. 2015;385(9966):421-9.
22. Ball J, Løchen M-L, Carrington MJ, Wiley JF, Stewart S. Mild cognitive impairment impacts health outcomes of patients with atrial fibrillation undergoing a disease management intervention. *Open Heart*. 2018;5(1):e000755.
23. Clark TJ, Middleton LJ, Am Cooper N, Diwakar L, Denny E, Smith P, et al. A randomised controlled trial of Outpatient versus inpatient Polyp Treatment (OPT) for abnormal uterine bleeding. *Health Technology Assessment* 2015;19(61).
24. Grubbs KM, Fortney JC, Pyne JM, Hudson T, Moore WM, Custer P, et al. Predictors of Initiation and Engagement of Cognitive Processing Therapy Among Veterans With PTSD Enrolled in Collaborative Care: Predictors of CPT Use in TOP. *Journal of Traumatic Stress*. 2015;28(6):580-4.
25. Handoll H, Brealey S, Jefferson L, Keding A, Brooksbank A, Johnstone A, et al. Defining the fracture population in a pragmatic multicentre randomised controlled trial. *Bone and Joint Research*. 2016;5(10):481-9.
26. Handoll H, Brealey S, Rangan A, Keding A, Corbacho B, Jefferson L, et al. The ProFHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial - a pragmatic multicentre randomised controlled trial evaluating the clinical effectiveness and cost-effectiveness of surgical compared with non-surgical treatment for proximal fracture of the humerus in adults. *Health Technology Assessment*. 2015;19(24).
27. Handoll H, Goodchild L, Brealey S, Hanchard N, Jefferson L, Keding A, et al. Developing, delivering and documenting rehabilitation in a multi-centre randomised controlled surgical trial. *Bone and Joint Research*. 2014;3(12):335-40.
28. Hall AM, Copsey B, Williams M, Srikesavan C, Lamb SE. Mediating Effect of Changes in Hand Impairments on Hand Function in Patients With Rheumatoid Arthritis: Exploring the Mechanisms of an Effective Exercise Program. *Arthritis Care and Research*. 2017;69(7):982-8.
29. Hill A-M, Waldron N, Francis-Coad J, Haines T, Etherton-Beer C. 'It promoted a positive culture around falls prevention': staff response to a patient education programme-a qualitative evaluation. *BMJ Open*. 2016;6(12):e013414.
30. Hill A-M, Francis-Coad J, Haines TP, Waldron N, Etherton-Beer C. 'My independent streak may get in the way': how older adults respond to falls prevention education in hospital. *BMJ Open*. 2016;6(7):e012363.
31. Hill A-M, McPhail SM, Francis-Coad J, Waldron N, Etherton-Beer C. Educators' perspectives about how older hospital patients can engage in a falls prevention education programme: a qualitative process evaluation. *BMJ Open*. 2015;5(12):e009780.
32. Keding A, Handoll H, Brealey S, Jefferson L, Hewitt C, Corbacho B, et al. The impact of surgeon and patient treatment preferences in an orthopaedic trauma surgery trial. *Trials*. 2019;20(1):570.
33. Knowles SE, Lovell K, Bower P, Gilbody S, Littlewood E, Lester H. Patient experience of computerised therapy for depression in primary care. *BMJ Open*. 2015;5(11):e008581.
34. Littlewood E, Duarte A, Hewitt C, Knowles S, Palmer S, Walker S, et al. A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. *Health Technology Assessment* 2015;19(101).
35. Nichols VP, Williamson E, Toye F, Lamb SE. A longitudinal, qualitative study exploring sustained adherence to a hand exercise programme for rheumatoid arthritis evaluated in the SARAH trial. *Disability and Rehabilitation*. 2017;39(18):1856-63.

36. Williams MA, Williamson EM, Heine PJ, Nichols V, Glover MJ, Dritsaki M, et al. Strengthening and Stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. *Health Technology Assessment*. 2015;19(19).
37. Novak DJ, Bai Y, Cooke RK, Marques MB, Fontaine MJ, Gottschall JL, et al. Making thawed universal donor plasma available rapidly for massively bleeding trauma patients: experience from the Pragmatic, Randomized Optimal Platelets and Plasma Ratios (PROPPR) trial. *Transfusion*. 2015;55(6):1331-9.
38. Sands G, Kelly D, Fletcher-Smith J, Birt L, Sackley C. An occupational therapy intervention for residents with stroke living in care homes in the United Kingdom: A content analysis of occupational therapy records from the OTCH trial. *British Journal of Occupational Therapy*. 2015;78(7):422-30.
39. Saville AW, Gurfinkel D, Sevic C, Beaty B, Dickinson LM, Kempe A. Provider Preferences and Experiences With a Countywide Centralized Collaborative Reminder/Recall for Childhood Immunizations. *Academic Pediatrics*. 2016;16(1):50-6.
40. Tjia J, Kutner JS, Ritchie CS, Blatchford PJ, Bennett Kendrick RE, Prince-Paul M, et al. Perceptions of statin discontinuation among patients with life-limiting illness. *Journal of Palliative Medicine*. 2017;20(10):1098-103.
41. Vennik J, Williamson I, Eyles C, Everitt H, Moore M. Nasal balloon autoinflation for glue ear in primary care: a qualitative interview study. *Br J Gen Pract*. 2019;69(678):e24-e32.
42. Williamson I, Vennik J, Harnden A, Voysey M, Perera R, Breen M, et al. An open randomised study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in primary care. *Health Technology Assessment*. 2015;19(72).
43. Moseley AM, Beckenkamp PR, Haas M, Herbert RD, Lin CW, Team E. Rehabilitation After Immobilization for Ankle Fracture: The EXACT Randomized Clinical Trial. *JAMA*. 2015;314(13):1376-85.
44. Fortney JC, Pyne JM, Kimbrell TA, Hudson TJ, Robinson DE, Schneider R, et al. Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(1):58-67.
45. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA*. 2015;313(5):471-82.
46. Honkoop PJ, Loijmans RJ, Termeer EH, Snoeck-Stroband JB, van den Hout WB, Bakker MJ, et al. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care. *Journal of Allergy & Clinical Immunology*. 2015;135(3):682-8.e11.
47. Gilbody S, Littlewood E, Hewitt C, Brierley G, Tharmanathan P, Araya R, et al. Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial. *BMJ*. 2015;351:h5627.
48. Sackley CM, Walker MF, Burton CR, Watkins CL, Mant J, Roalfe AK, et al. An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation. *Health Technology Assessment*. 2016;20(15).
49. O'Cathain A, Thomas K, Drabble S, Rudolph A, Hewison J. What can qualitative research do for randomised controlled trials? A systematic mapping review. *BMJ open*. 2013;3(6):e002889.
50. Bakker FC, Persoon A, Schoon Y, Olde Rikkert MGM. Uniform presentation of process evaluation results facilitates the evaluation of complex interventions: development of a graph: Presenting process evaluation's results. *Journal of Evaluation in Clinical Practice*. 2015;21(1):97-102.
51. Morgan-Trimmer S, Wood F. Ethnographic methods for process evaluations of complex health behaviour interventions. *Trials*. 2016;17(1):232.
52. Wells M, Williams B, Treweek S, Coyle J, Taylor J. Intervention description is not enough: evidence from an in-depth multiple case study on the untold role and impact of context in randomised controlled trials of seven complex interventions. *Trials*. 2012;13(1):95-.
53. Oakley A. Evaluating Processes A Case Study of a Randomized Controlled Trial of Sex Education. *Evaluation (London, England 1995)*. 2004;10(4):440-62.

54. Zwarenstein M, Treweek S, Gagnier JJ, Altman DG, Tunis S, Haynes B, et al. Improving the reporting of pragmatic trials: an extension of the CONSORT statement. *BMJ*. 2008;337.
55. Boutron I, Altman DG, Moher D, Schulz KF, Ravaud P. CONSORT statement for randomized trials of nonpharmacologic treatments: a 2017 update and a CONSORT extension for nonpharmacologic trial abstracts. *Annals of internal medicine*. 2017;167(1):40-7.

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



Additional file 1

MEDLINE (Ovid) search strategy

Search conducted via Ovid (MEDLINE)[®] and Epub Ahead of Print In-Process & Other Non-Indexed Citations, Daily and Versions[®]

1. (pragmatic and trial).mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept word, rare disease supplementary concept word, unique identifier, synonyms]
2. limit 1 to (english language and humans and "core clinical journals (aim)" and yr="2015" and (clinical trial, all or clinical trial or controlled clinical trial or pragmatic clinical trial or randomized controlled trial))

Additional file 2 - trial descriptor data fields

Data field	Operationalisation	Extract from	Extract as
Funder	Who funded the trial	Trial results paper, or trial registry if not stated	Free text
Publication month	Month the trial results paper was published in print, or online for online only journals	Medline search result	Month
Publication year	Year the trial results paper was published in print, or online for online only journals	Medline search result	2015
Country	The country / countries the intervention was delivered in during the trial	Trial results paper	Country
Journal	The journal the trial results paper was published in	Trial results paper	Journal name
Intervention	Brief description of intervention(s)	Trial results paper	Free text
Comparator	What was received by the control / comparator group(s)	Trial results paper	Free text
Intervention recipients	Who received the intervention	Trial results paper	Free text
Intervention deliverer	Who administered / delivered the intervention(s) during the trial	Trial results paper	Free text
Clinical specialty	The clinical field the intervention was intended for	Trial results paper	Free text
Setting	The setting of intervention delivery.	Trial results paper	Free text
Randomisation level	Whether participants were individually or cluster randomised	Trial results paper	Individual Cluster
Primary outcome result	Whether the primary outcome result was stated as being statistically significant in the abstract of the paper (p value or confidence interval)	Trial results paper – abstract If not clear from abstract class as unclear If classification does not fit e.g. non-inferiority, multiple outcomes, class as n/a	Positive Not positive n/a if does not fit
Trial design	Further details of the trial design	Trial results paper	2-arm 3-arm Non-inferiority Stepped-wedge Crossover

Additional file 3

Section/topic	#	Checklist item	Reported on page #
TITLE			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2-3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3-5
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	3
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	6-7
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	6-7
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	6 (Add. file 1)
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	6-8
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	7-9
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	8-9 (add. File 2)

Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	n/a
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	n/a
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	8-9

Additional file 4 - included pragmatic RCTs

Reference of index trial results paper <i>Journal</i> Country Further references*	Intervention	MRC process evaluation components reported in index trial results paper(s)										Participant responses	Separate process evaluation paper(s)
		Reach	Fidelity	Dose	How delivery is achieved	Adaptations	Contextual moderators	Contextual factors that shape intervention theory	Causal mechanisms that maintain status quo or enhance effects	Mediators	Unanticipated pathways and consequences		
Bartels 2015 (1) <i>American Journal of Psychiatry</i> USA	Health promotion coaching for obesity in serious mental illness	Y					Y	Y	Y	Y		Y	No (included process evaluation but using data from multiple trials so excluded from review)
Bender 2015 (2) <i>JAMA Pediatrics</i> USA	Speech recognition telephone calls to improve adherence to child asthma treatment	Y					Y	Y				Y	No
Boulvain 2015 (3) <i>Lancet</i> France, Belgium, Switzerland	Induction of labour vs expectant management for large-for-date fetuses	Y											No
Cooper 2015 (4) <i>BMJ</i> UK Clark 2015 (5)	Outpatient vs inpatient uterine polyp treatment	Y					Y		Y		Y	Y	Yes
Curtis 2015 (6) <i>Canadian Medical Association Journal</i> Canada	Ultrasound or near-infrared vascular imaging to guide peripheral intravenous catheterisation	Y					Y	Y					No
El-Khoury 2015 (7) <i>BMJ</i> France	Balance training to prevent fall-induced injuries	Y		Y							Y	Y	No

Reference of index trial results paper <i>Journal</i> Country Further references*	Intervention	MRC process evaluation components reported in index trial results paper(s)											Separate process evaluation paper(s)
		Reach	Fidelity	Dose	How delivery is achieved	Adaptations	Contextual moderators	Contextual factors that shape intervention theory	Causal mechanisms that maintain status quo or enhance effects	Mediators	Unanticipated pathways and consequences	Participant responses	
Fortney 2015 (8) <i>JAMA Psychiatry</i> USA	Telemedicine-based collaborative care for veterans with PTSD	Y	Y	Y		Y				Y		Y	Yes
Gilbody 2015 (9) <i>BMJ</i> UK Littlewood 2015 (10)	Computerised cognitive behavioural therapy for depression	Y					Y		Y		Y	Y	Yes
Hill 2015 (11) <i>Lancet</i> Australia	Individualised falls-prevention education for hospital patients, with training and feedback for staff	Y	Y	Y			Y	Y			Y	Y	Yes
Holcomb 2015 (12) <i>JAMA</i> North America Baraniuk 2014 (13) Zhu 2016 (14)	Comparison of 2 different ratios of blood products in patients with major trauma	Y	Y			Y							Yes
Honkoop 2015 (15) <i>Journal of Allergy and Clinical Immunology</i> Netherlands	Comparison of 3 treatment strategies targeting different levels of asthma control	Y	Y									Y	No
Hui 2015 (16) <i>Gut</i> Hong Kong	Comparison of medical and nurse endoscopists performing colonoscopy	Y				Y	Y					Y	No

Reference of index trial results paper <i>Journal</i> Country Further references*	Intervention	MRC process evaluation components reported in index trial results paper(s)											Separate process evaluation paper(s)
		Reach	Fidelity	Dose	How delivery is achieved	Adaptations	Contextual moderators	Contextual factors that shape intervention theory	Causal mechanisms that maintain status quo or enhance effects	Mediators	Unanticipated pathways and consequences	Participant responses	
Kempe 2015 (17) <i>JAMA Pediatrics</i> USA	Collaborative centralised reminder/recall system to increase immunisation rates in young children	Y				Y		Y			Y		Yes
Knowles 2015 (18) <i>Lancet</i> UK Horrocks 2015 (19)	Percutaneous tibial nerve stimulation for treatment of faecal incontinence	Y	Y				Y				Y	Y	No
Kutner 2015 (20) <i>JAMA Internal Medicine</i> USA	Statin discontinuation in advanced life-limiting illness	Y									Y	Y	Yes
Lamb 2015 (21) <i>Lancet</i> UK Williams 2015 (22)	Exercises to improve hand function in rheumatoid arthritis	Y	Y	Y		Y	Y	Y	Y		Y	Y	Yes
Moreira 2015 (23) <i>Nursing Research</i> Brazil	Nursing case management for patients with type 2 diabetes	Y					Y		Y				No
Moseley 2015 (24) <i>JAMA</i> Australia	Exercise programme for rehabilitation following ankle fracture	Y	Y				Y		Y		Y	Y	No
Mouncey 2015a (25) <i>NEJM</i> UK Mouncey 2015b (26)	Early, Goal-Directed Resuscitation protocol for septic shock	Y	Y			Y	Y	Y	Y		Y		No

Reference of index trial results paper <i>Journal</i> Country Further references*	Intervention	MRC process evaluation components reported in index trial results paper(s)											Separate process evaluation paper(s)
		Reach	Fidelity	Dose	How delivery is achieved	Adaptations	Contextual moderators	Contextual factors that shape intervention theory	Causal mechanisms that maintain status quo or enhance effects	Mediators	Unanticipated pathways and consequences	Participant responses	
Noto 2015 (27) <i>JAMA</i> USA	Chlorhexadine bathing in intensive care units	Y	Y				Y						No
Perkins 2015 (28) <i>Lancet</i> UK Gates 2017 (29)	Mechanical vs manual chest compression for out of hospital cardiac arrest	Y	Y				Y		Y		Y		No
Rangan 2015 (30) <i>JAMA</i> UK Handoll 2015 (31)	Surgical vs non-surgical treatment for adults with displaced fracture of proximal humerus	Y	Y			Y	Y		Y		Y	Y	Yes
Sackley 2015 (32) <i>BMJ</i> UK Sackley 2016 (33)	Occupational therapy for care home residents with stroke disability	Y		Y			Y	Y			Y		Yes
Scott 2015 (34) <i>BMJ</i> UK Scott 2014 (35)	Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs	Y				Y		Y			Y	Y	No
Semler 2015 (36) <i>Critical Care Medicine</i> USA	Electronic sepsis evaluation and management tool in intensive care	Y		Y		Y	Y					Y	No
Smith 2015a (37) <i>BMJ</i> UK	Patient-controlled analgesia for patients in emergency	Y									Y	Y	No

Reference of index trial results paper <i>Journal</i> Country Further references*	Intervention	MRC process evaluation components reported in index trial results paper(s)											Separate process evaluation paper(s)
		Reach	Fidelity	Dose	How delivery is achieved	Adaptations	Contextual moderators	Contextual factors that shape intervention theory	Causal mechanisms that maintain status quo or enhance effects	Mediators	Unanticipated pathways and consequences	Participant responses	
	department with pain from traumatic injuries												
Smith 2015b (38) <i>BMJ</i> UK	Patient-controlled analgesia for patients in emergency department with pain from non-traumatic abdominal injuries	Y									Y	Y	No
Stewart 2015 (39) <i>Lancet</i> Australia	Standard vs atrial-fibrillation specific management strategy	Y	Y	Y		Y			Y				Yes
Wechsler 2015 (40) <i>JAMA</i> USA	Anticholinergic vs long-acting β -agonist in combination with inhaled corticosteroids in black adults with asthma	Y				Y	Y				Y	Y	No
Westendorp 2015 (41) <i>Lancet</i> Netherlands	Preventive antibiotics in stroke	Y		Y			Y	Y	Y		Y		No
Williamson 2015 (42) <i>Canadian Medical Association Journal</i> UK Williamson 2015 (43)	Nasal balloon autoinflation in children with otitis media with effusion in primary care	Y					Y		Y		Y	Y	Yes

*If applicable - references of additional publications reporting trial results from which we extracted data on process evaluation components

References

1. Bartels SJ, Pratt SI, Aschbrenner KA, Barre LK, Naslund JA, Wolfe R, et al. Pragmatic replication trial of health promotion coaching for obesity in serious mental illness and maintenance of outcomes. *American Journal of Psychiatry*. 2015;172(4):344-52.
2. Bender BG, Cvietusa PJ, Goodrich GK, Lowe R, Nuanes HA, Rand C, et al. Pragmatic trial of health care technologies to improve adherence to pediatric asthma treatment: a randomized clinical trial. *JAMA Pediatrics*. 2015;169(4):317-23.
3. Boulvain M, Senat MV, Perrotin F, Winer N, Beucher G, Subtil D, et al. Induction of labour versus expectant management for large-for-date fetuses: a randomised controlled trial. *Lancet*. 2015;385(9987):2600-5.
4. Cooper NA, Clark TJ, Middleton L, Diwakar L, Smith P, Denny E, et al. Outpatient versus inpatient uterine polyp treatment for abnormal uterine bleeding: randomised controlled non-inferiority study. *BMJ*. 2015;350:h1398.
5. Clark TJ, Middleton LJ, Am Cooper N, Diwakar L, Denny E, Smith P, et al. A randomised controlled trial of Outpatient versus inpatient Polyp Treatment (OPT) for abnormal uterine bleeding. *Health Technology Assessment* 2015;19(61).
6. Curtis SJ, Craig WR, Logue E, Vandermeer B, Hanson A, Klassen T. Ultrasound or near-infrared vascular imaging to guide peripheral intravenous catheterization in children: a pragmatic randomized controlled trial. *CMAJ Canadian Medical Association Journal*. 2015;187(8):563-70.
7. El-Khoury F, Cassou B, Latouche A, Aegerter P, Charles MA, Dargent-Molina P. Effectiveness of two year balance training programme on prevention of fall induced injuries in at risk women aged 75-85 living in community: Ossebo randomised controlled trial. *BMJ*. 2015;351:h3830.
8. Fortney JC, Pyne JM, Kimbrell TA, Hudson TJ, Robinson DE, Schneider R, et al. Telemedicine-based collaborative care for posttraumatic stress disorder: a randomized clinical trial. *JAMA Psychiatry*. 2015;72(1):58-67.
9. Gilbody S, Littlewood E, Hewitt C, Brierley G, Tharmanathan P, Araya R, et al. Computerised cognitive behaviour therapy (cCBT) as treatment for depression in primary care (REEACT trial): large scale pragmatic randomised controlled trial. *BMJ*. 2015;351:h5627.
10. Littlewood E, Duarte A, Hewitt C, Knowles S, Palmer S, Walker S, et al. A randomised controlled trial of computerised cognitive behaviour therapy for the treatment of depression in primary care: the Randomised Evaluation of the Effectiveness and Acceptability of Computerised Therapy (REEACT) trial. *Health Technology Assessment* 2015;19(101).
11. Hill AM, McPhail SM, Waldron N, Etherton-Beer C, Ingram K, Flicker L, et al. Fall rates in hospital rehabilitation units after individualised patient and staff education programmes: a pragmatic, stepped-wedge, cluster-randomised controlled trial. *Lancet*. 2015;385(9987):2592-9.
12. Holcomb JB, Tilley BC, Baraniuk S, Fox EE, Wade CE, Podbielski JM, et al. Transfusion of plasma, platelets, and red blood cells in a 1:1:1 vs a 1:1:2 ratio and mortality in patients with severe trauma: the PROPPR randomized clinical trial. *JAMA*. 2015;313(5):471-82.
13. Baraniuk S, Tilley BC, del Junco DJ, Fox EE, van Belle G, Wade CE, et al. Pragmatic Randomized Optimal Platelet and Plasma Ratios (PROPPR) Trial: design, rationale and implementation. *Injury*. 2014;45(9):1287-95.
14. Zhu H, Fox EE, Baraniuk S, Holcomb JB, Wade CE. Assessing protocol adherence in a clinical trial with ordered treatment regimens: Quantifying the pragmatic, randomized optimal platelet and plasma ratios (PROPPR) trial experience. *Injury*. 2016;47(10):2131-7.
15. Honkoop PJ, Loijmans RJ, Termeer EH, Snoeck-Stroband JB, van den Hout WB, Bakker MJ, et al. Symptom- and fraction of exhaled nitric oxide-driven strategies for asthma control: A cluster-randomized trial in primary care. *Journal of Allergy & Clinical Immunology*. 2015;135(3):682-8.e11.

16. Hui AJ, Lau JY, Lam PP, Chui AO, Fan AS, Lam TY, et al. Comparison of colonoscopic performance between medical and nurse endoscopists: a non-inferiority randomised controlled study in Asia. *Gut*. 2015;64(7):1058-62.
17. Kempe A, Saville AW, Dickinson LM, Beaty B, Eisert S, Gurfinkel D, et al. Collaborative centralized reminder/recall notification to increase immunization rates among young children: a comparative effectiveness trial. *JAMA Pediatrics*. 2015;169(4):365-73.
18. Knowles CH, Horrocks EJ, Bremner SA, Stevens N, Norton C, O'Connell PR, et al. Percutaneous tibial nerve stimulation versus sham electrical stimulation for the treatment of faecal incontinence in adults (CONFIDeNT): a double-blind, multicentre, pragmatic, parallel-group, randomised controlled trial. *Lancet*. 2015;386(10004):1640-8.
19. Horrocks EJ, Bremner SA, Stevens N, Norton C, Gilbert D, O'Connell PR, et al. Double-blind randomised controlled trial of percutaneous tibial nerve stimulation versus sham electrical stimulation in the treatment of faecal incontinence: CONtrol of Faecal Incontinence using Distal Neuromodulation (the CONFIDeNT trial). *Health Technology Assessment*. 2015;19(77).
20. Kutner JS, Blatchford PJ, Taylor DH, Jr., Ritchie CS, Bull JH, Fairclough DL, et al. Safety and benefit of discontinuing statin therapy in the setting of advanced, life-limiting illness: a randomized clinical trial.[Erratum appears in *JAMA Intern Med*. 2015 May;175(5):869; PMID: 25938325]. *JAMA Internal Medicine*. 2015;175(5):691-700.
21. Lamb SE, Williamson EM, Heine PJ, Adams J, Dosanjh S, Dritsaki M, et al. Exercises to improve function of the rheumatoid hand (SARAH): a randomised controlled trial. *Lancet*. 2015;385(9966):421-9.
22. Williams MA, Williamson EM, Heine PJ, Nichols V, Glover MJ, Dritsaki M, et al. Strengthening And stretching for Rheumatoid Arthritis of the Hand (SARAH). A randomised controlled trial and economic evaluation. *Health Technology Assessment*. 2015;19(19).
23. Moreira RC, Mantovani Mde F, Soriano JV. Nursing Case Management and Glycemic Control Among Brazilians With Type 2 Diabetes: Pragmatic Clinical Trial. *Nursing Research*. 2015;64(4):272-81.
24. Moseley AM, Beckenkamp PR, Haas M, Herbert RD, Lin CW, Team E. Rehabilitation After Immobilization for Ankle Fracture: The EXACT Randomized Clinical Trial. *JAMA*. 2015;314(13):1376-85.
25. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Trial of early, goal-directed resuscitation for septic shock. *New England Journal of Medicine*. 2015;372(14):1301-11.
26. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Grieve RD, et al. Protocolised Management In Sepsis (ProMISe): a multicentre randomised controlled trial of the clinical effectiveness and cost-effectiveness of early, goal-directed, protocolised resuscitation for emerging septic shock. *Health Technology Assessment*. 2015;19(97).
27. Noto MJ, Domenico HJ, Byrne DW, Talbot T, Rice TW, Bernard GR, et al. Chlorhexidine bathing and health care-associated infections: a randomized clinical trial. *JAMA*. 2015;313(4):369-78.
28. Perkins GD, Lall R, Quinn T, Deakin CD, Cooke MW, Horton J, et al. Mechanical versus manual chest compression for out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised controlled trial. *Lancet*. 2015;385(9972):947-55.
29. Gates S, Lall RS, Quinn T, Deakin CD, Cooke M, Horton J, et al. Prehospital randomised assessment of a mechanical compression device in out-of-hospital cardiac arrest (PARAMEDIC): a pragmatic, cluster randomised trial and economic evaluation. *Health Technology Assessment*. 2017;21(11):1-176.

30. Rangan A, Handoll H, Brealey S, Jefferson L, Keding A, Martin BC, et al. Surgical vs nonsurgical treatment of adults with displaced fractures of the proximal humerus: the PROFHER randomized clinical trial. *JAMA*. 2015;313(10):1037-47.
31. Handoll H, Brealey S, Rangan A, Keding A, Corbacho B, Jefferson L, et al. The ProfHER (PROximal Fracture of the Humerus: Evaluation by Randomisation) trial - a pragmatic multicentre randomised controlled trial evaluating the clinical effectiveness and cost-effectiveness of surgical compared with non-surgical treatment for proximal fracture of the humerus in adults. *Health Technology Assessment*. 2015;19(24).
32. Sackley CM, Walker MF, Burton CR, Watkins CL, Mant J, Roalfe AK, et al. An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial. *BMJ*. 2015;350:h468.
33. Sackley CM, Walker MF, Burton CR, Watkins CL, Mant J, Roalfe AK, et al. An Occupational Therapy intervention for residents with stroke-related disabilities in UK Care Homes (OTCH): cluster randomised controlled trial with economic evaluation. *Health Technology Assessment*. 2016;20(15).
34. Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Walker D, Kelly C, et al. Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial. *BMJ*. 2015;350:h1046.
35. Scott DL, Ibrahim F, Farewell V, O'Keeffe AG, Ma M, Walker D, et al. Randomised controlled trial of tumour necrosis factor inhibitors against combination intensive therapy with conventional disease-modifying antirheumatic drugs in established rheumatoid arthritis: the TACIT trial and associated systematic reviews. *Health Technology Assessment*. 2014;18(66).
36. Semler MW, Weaver LW, Hooper MH, Rice TW, Gowda SS, Nadas A, et al. An Electronic Tool for the Evaluation and Treatment of Sepsis in the ICU: A Randomized Controlled Trial. *Critical Care Medicine*. 2015;43(8):1595-602.
37. Smith JE, Rockett M, S SC, Squire R, Hayward C, Ewings P, et al. PAin SoluTions In the Emergency Setting (PASTIES)--patient controlled analgesia versus routine care in emergency department patients with pain from traumatic injuries: randomised trial. *BMJ*. 2015;350:h2988.
38. Smith JE, Rockett M, Creanor S, Squire R, Hayward C, Ewings P, et al. PAin SoluTions In the Emergency Setting (PASTIES)—patient controlled analgesia versus routine care in emergency department patients with non-traumatic abdominal pain: randomised trial. *bmj*. 2015;350:h3147.
39. Stewart S, Ball J, Horowitz JD, Marwick TH, Mahadevan G, Wong C, et al. Standard versus atrial fibrillation-specific management strategy (SAFETY) to reduce recurrent admission and prolong survival: pragmatic, multicentre, randomised controlled trial. *Lancet*. 2015;385(9970):775-84.
40. Wechsler ME, Yawn BP, Fuhlbrigge AL, Pace WD, Pencina MJ, Doros G, et al. Anticholinergic vs Long-Acting beta-Agonist in Combination With Inhaled Corticosteroids in Black Adults With Asthma: The BELT Randomized Clinical Trial. *JAMA*. 2015;314(16):1720-30.
41. Westendorp WF, Vermeij JD, Zock E, Hooijenga IJ, Kruijff ND, Bosboom HJ, et al. The Preventive Antibiotics in Stroke Study (PASS): a pragmatic randomised open-label masked endpoint clinical trial. *Lancet*. 2015;385(9977):1519-26.
42. Williamson I, Vennik J, Harnden A, Voysey M, Perera R, Kelly S, et al. Effect of nasal balloon autoinflation in children with otitis media with effusion in primary care: an open randomized controlled trial. *CMAJ Canadian Medical Association Journal*. 2015;187(13):961-9.
43. Williamson I, Vennik J, Harnden A, Voysey M, Perera R, Breen M, et al. An open randomised study of autoinflation in 4- to 11-year-old school children with otitis media with effusion in primary care. *Health Technology Assessment*. 2015;19(72).

Additional file 5

Items mapped to each process evaluation component

MRC component	Included items
Implementation	
Adaptations <i>Alterations made to an intervention in order to achieve better contextual fit</i>	<p>Trial papers</p> <ul style="list-style-type: none"> • Time taken to deliver interventions where this was not specified by a protocol • Means through which the intervention was delivered where this was flexible, e.g. qualifications of staff delivering the intervention • Which intervention components were delivered to participants as part of flexible interventions • Description of alternative materials used by sites to trial materials <p>Process evaluation papers</p> <ul style="list-style-type: none"> • Description of how a flexible intervention was delivered in practice
Dose <i>How much intervention is delivered</i>	<p>Trial papers</p> <ul style="list-style-type: none"> • Numbers of intervention sessions delivered to participants • Numbers of 'occurrences' of optional intervention components delivered to participants • Numbers of times the intervention electronic tool was opened • Time spent by deliverers on intervention components
Fidelity <i>The consistency of what is implemented with the planned intervention</i>	<p>Trial papers</p> <ul style="list-style-type: none"> • Whether or not intervention components were delivered • The quality or standard of (components of) interventions delivered • Reasons for non-adherence or protocol deviations • Fidelity scores, adherence percentages • Whether or not the correct randomised intervention was delivered • Analyses to examine the effect of non-fidelity on the primary outcome – e.g. per-protocol, complier average causal effect analyses <p>Process evaluation papers</p> <ul style="list-style-type: none"> • Whether and how centres delivered interventions in accordance with intervention protocols
How delivery is achieved	<p>Process evaluation papers</p> <ul style="list-style-type: none"> • Qualitative exploration of perceptions of intervention deliverers

MRC component	Included items
<i>The structures, resources and mechanisms through which delivery is achieved</i>	<ul style="list-style-type: none"> Measures taken to ensure fidelity to intervention and usual care protocols
Reach <i>Extent to which target audience comes into contact with intervention</i>	<p>Trial papers</p> <ul style="list-style-type: none"> Trial flow diagrams / CONSORT diagrams Reasons for non-participation, exclusion, drop-out Participant and site characteristics Numbers of participants recruited from different sites Numbers of participants who received the randomised intervention Comparison of demographics between those who declined participation and trial participants Characteristics of screened but not randomised patients Reach of interventions delivered to randomised populations Comparison of demographics between participants completing and not completing follow-up Comparison of site characteristics with all departments in the country Comparison of participant characteristics with national patient population Length of time sites open to recruitment, length of time between obtaining site NHS permission and opening to recruitment Independent rating of reasons for patients being judged ineligible by sites Subgroup analysis comparing outcomes between patients randomised to receive the intervention who answered and did not answer at least one call. Sample attrition bias Sensitivity analysis of primary outcome including participants with missing outcomes Sensitivity analysis excluding participants from 2 poorly recruiting centres Associations between participant characteristics and the completeness of response to providing follow-up data <p>Process evaluation papers</p> <ul style="list-style-type: none"> Interviews with healthcare professionals about the degree to which they targeted recruitment to patients deemed most suitable, and perceptions about which patients were most suitable for the intervention.

MRC component	Included items
	<ul style="list-style-type: none"> • Patient motivations for agreeing or declining trial participation • Measures taken to ensure inclusion of intended trial population in pragmatic trial
Context	
Causal mechanisms that act to maintain the status quo, or enhance effects	<p>Trial papers</p> <ul style="list-style-type: none"> • Details of usual care received by participants • Use of similar interventions by usual care group, impact of use on outcomes • Change in medication use by trial participants during the intervention period • Impact of concurrent interventions • Seasonal effects <p>Process evaluation papers</p> <ul style="list-style-type: none"> • Participant reported barriers and facilitators to engaging with or adhering to the intervention
Contextual factors that shape theory of how the intervention works	<p>Trial papers</p> <ul style="list-style-type: none"> • Effect of time on effectiveness of the intervention – e.g. cumulative unit level effect of intervention, learning curve effects • Effect of intervention variables e.g. phone calls by answering machine or in person • Ceiling effect of intervention depending on participant baseline level of disability • Comparison of outcomes between participants who kept taking same regime and those who switched partway through <p>Process evaluation papers</p> <ul style="list-style-type: none"> • Qualitative findings discussing potential factors influencing intervention outcomes e.g. skills, experience, personalities and abilities of intervention deliverers
Contextual moderators <i>Shape, and may be shaped by, implementation, intervention mechanisms, and outcomes</i>	<p>Trial papers</p> <ul style="list-style-type: none"> • Analyses of effect of moderators on outcomes, e.g. participant age, gender, smoking status, cognition, treatment preferences, site characteristics <p>Process evaluation papers</p> <ul style="list-style-type: none"> • In qualitative studies – findings about factors which could potentially modify intervention effect

MRC component	Included items
Mechanisms of impact	
Mediators <i>Intermediate processes which explain subsequent changes in outcome</i>	Trial papers <ul style="list-style-type: none"> Effect of participant usage of different intervention components on primary outcome Process evaluation papers <ul style="list-style-type: none"> Mediation analysis of proximal intervention effects
Participant responses <i>How participants interact with a complex intervention</i>	Trial papers <ul style="list-style-type: none"> Uptake and use of the intervention, or components of the intervention, by trial participants, e.g. number of sessions attended Analyses to examine the effect of adherence to or completion of an intervention or its components on the primary outcome Subgroup analyses to investigate the effect of certain participant characteristics on level compliance with intervention Participant satisfaction with treatment Participant perceptions of which treatment they had received, treatment preferences at end of trial Procedure acceptability to participants Process-of-care outcome e.g. medication adherence, accessing therapies Process evaluation papers <ul style="list-style-type: none"> Qualitative research exploring patient adherence, perceptions, experiences of interventions Quantitative questionnaire about participant perceptions of the benefits and harms of the intervention
Unintended pathways and consequences	Trial papers <ul style="list-style-type: none"> Participant adverse events Process evaluation papers <ul style="list-style-type: none"> Qualitative findings included reports of unanticipated consequences

Additional file 6

All extracted values of process evaluation

Value category with details	Process evaluations reporting this value (n=17)
Adding value to the intervention	
Supporting implementation of the intervention into practice <ul style="list-style-type: none"> • Targeting or tailoring the intervention to specific patients • Aiding replication of a complex intervention • Understanding how patients engage with the intervention • Understanding providers' viewpoints and willingness to collaborate • Developing tools / strategies for implementation • Targeting the intervention to specific groups • Highlighting important components of the intervention to implementers • Highlighting benefits of the intervention to promote uptake • Highlighting effective delivery strategies • Providing evidence of feasibility / acceptability • Tailoring delivery to different groups • Highlighting importance of roles of different people / agencies in ensuring successful delivery • Addressing barriers to implementation or uptake of the intervention • Recommendations for training or support to participants or deliverers • Suggesting how intervention could fit into existing care pathways • Highlighting potential disadvantages of the intervention • Recommendations for information to give to patients considering intervention • Recommendations for clinicians to help decide between interventions • Recommendations for further intervention implementation research • Highlighting lack of equipoise in deliverers 	15
Improving the intervention Recommendations for further development of the intervention based on process evaluation findings: <ul style="list-style-type: none"> • Recommendations to keep all components of the intervention • Adding stronger monitoring protocols to promote adherence • Adaptations to design for patients with reduced cognition Recommendations for further research relating to the intervention:	10

Value category with details	Process evaluations reporting this value (n=17)
<ul style="list-style-type: none"> • Effectiveness over time • Effectiveness in different contexts • Different modes of delivery e.g. group settings • Intervention refinement, e.g. to improve patient experience 	
Addressing a concern identified about the intervention <ul style="list-style-type: none"> • Acceptability of the intervention to patients / deliverers • Participant adherence • Complexity of intervention delivery • Influence of participant cognition on intervention effectiveness 	7
Understanding how the intervention works <ul style="list-style-type: none"> • Intervention mechanisms • Content delivered in a flexible intervention 	4
Adding value to the RCT	
Providing reasons for trial results <ul style="list-style-type: none"> • Possible reasons for non-positive trial results • Explanations for positive trial results • Explanations for other trial data 	8
Adding information not provided by the trial <ul style="list-style-type: none"> • Participant or deliverer concerns • Key components of intervention • Added clarification, nuance, context • Perspectives of participants after time for reflection • Concurrent treatments received by trial participants • Experiences and perceptions – things important to participants, minority views 	6
Increasing accuracy of trial results <ul style="list-style-type: none"> • Assessing comparability of standard care between both randomised groups • Qualitative findings helping confirm quantitative data on satisfaction • Avoid survivor bias • Accurately define the trial population and facilitate purpose and interpretation of trial • Investigating threats to internal and external validity 	6

Value category with details	Process evaluations reporting this value (n=17)
Building on trial data <ul style="list-style-type: none"> Explore findings from a subgroup analysis conducted in the main trial Expand on the quantitative questionnaire data collected in the main trial about participant acceptability and satisfaction Identified adverse events not reported in the main trial data collection 	3
Understanding the applicability of trial results <ul style="list-style-type: none"> Evaluating whether the intended pragmatic trial population was achieved in the trial Investigating threats to external validity from patient or provider treatment preference 	2
Meeting trial reporting requirements <ul style="list-style-type: none"> Meeting CONSORT requirements for pragmatic and nonpharmacologic trials 	1
Meeting recommendation to conduct process evaluation <ul style="list-style-type: none"> Citing recommendation by MRC process evaluation framework to conduct mediation analysis 	1
Explaining issues with trial conduct <ul style="list-style-type: none"> Reasons for requiring recruitment extension 	1
Adding value external to the intervention or RCT	
Contributing to wider knowledge <ul style="list-style-type: none"> Future trial design Understanding patient populations and patient experiences Understanding the problem addressed by the intervention Improving clinical practice in the field Informing design of similar interventions Highlighting that findings supported or refuted the existing knowledge base Methodological recommendations 	16
Improving usual care at trial sites <ul style="list-style-type: none"> Highlighting gaps in current care provision 	1